25 of the Best Hematologists Near Me in rosedale, MD

Dr. Shruti Chaturvedi is an Associate Professor of Medicine at Johns Hopkins. She received her medical degree from Maulana Azad Medical College, University of Delhi, India. She then completed a residency in Internal Medicine at the Cleveland Clinic, Cleveland, OH, and a fellowship in Hematology and Oncology at Vanderbilt University, Nashville, TN. She has additionally obtained a Master of Science in Clinical Investigation (MSCI) degree from Vanderbilt University. Dr. Chaturvedi specializes in the care of adults with non-malignant hematologic disorders including thrombocytopenic purpura, atypical hemolytic uremic syndrome, antiphospholpiid syndrome, immune thrombocytopenia, autoimmune hemolytic anemia, thrombotic, other bleeding and clotting disorders, and anemias. Her research is focused on improving the care of patients with thrombotic microangiopathies with a focus on long term sequelae, and the role of complement in thrombotic disorders such as the antiphospholipid syndrome. Dr. Chaturvedi is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), Blood Clots, Splenectomy, and Bone Marrow Aspiration. Dr. Chaturvedi is currently accepting new patients.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma. Dr. Hann is board certified in American Board Of Internal Medicine. Dr. Hann is currently accepting new patients.

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is board certified in American Board Of Internal Medicine. Dr. Brodsky is currently accepting new patients.

As a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins, my focus is on the various aspects of cellular therapy in the treatment of hematological malignancies. My primary research focus is to develop strategies to prevent relapse of hematological malignancies following allogeneic stem cell transplantation. Additionally, I serve as the director of the adult CAR T program for hematological malignancies as we grow our CAR T program to help patients with advanced hematological malignancies. My academic interest in this space lies in studying the aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients. Among hematological malignancies, myeloproliferative disorders are my area of interest and I work to study newer drugs in early phase of development and also its treatment using allogeneic stem cell transplantation. Patient appointments: 410-955-8893. Dr. Jain is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Splenectomy. Dr. Jain is board certified in American Board Of Internal Medicine. Dr. Jain is currently accepting new patients.

Dr. Rakhi P. Naik is the Associate Director for the Division of Hematology at Johns Hopkins University. She also serves as Director of the Fellowship Hematology Track and Director of Organ Systems Foundation of Medicine (OSFM), the largest pre-clerkship course in the medical school. She holds an undergraduate degree in Biomedical & Electrical Engineering from Duke University, an M.D. with. Dr. Naik is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemolytic Anemia, Hemoglobinopathy, and Congenital Hemolytic Anemia. Dr. Naik is board certified in American Board Of Internal Medicine. Dr. Naik is currently accepting new patients.

Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program. She has served on the National Cancer Institute (NCI) Investigational Drug Steering Committee since 2014. Dr. Gojo received a Service Star Award from Johns Hopkins Medicine Service Excellence in 2018 for her exemplary care of leukemia patients. Dr. Gojo contributed to the clinical translational and drug development effort of multiple novel agents targeting pathogenic pathways in patients with acute leukemia. Her research efforts are now concentrated on the development and integration of novel immunotherapies into therapeutic armamentarium for patients with acute leukemia. She mentors basic and clinical research fellows and junior faculty on the development and design of novel clinical trials and mechanistic laboratory studies associated with these trials. She served as a leukemia team leader on the National Institute of Health (NIH)/NCI N01 grant (Phase II consortium) (2009-2011), and is co-principal investigator (PI) on the Experimental Therapeutics (ET)-Clinical Trial Network (CTN) UM1 grant supporting early clinical trials. Dr. Gojo has served on the National Comprehensive Cancer Network guideline panel for AML since 2019, Myeloid Growth Factor guideline panel since 2015 and previously served on the MPNs guideline panel (2016-2019). She has extensive experience in the regulatory aspects of drug development and served as the Chair (2015-2016) and Co-Chair (2014-2015) of the Cancer Research Review Committee at Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, and serves as a member of the SKCCC Biostatistics Core Advisory Committee and SKCCC Clinical Research Office Coordinating Center Oversight Committee. Dr. Gojo is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Gojo is board certified in American Board Of Internal Medicine. Dr. Gojo is currently accepting new patients.

Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Metastatic Uveal Melanoma, and Melanoma of the Eye. Dr. Lipson is board certified in American Board Of Internal Medicine. Dr. Lipson is currently accepting new patients.

Dr. Gloria F. Gerber is an Assistant Professor of Medicine at Johns Hopkins University in the Division of Hematology. She received her undergraduate degree in Biology with High. Dr. Gerber is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Hemolysis, and Hemolytic Anemia. Dr. Gerber is board certified in American Board Of Internal Medicine. Dr. Gerber is currently accepting new patients.

Dr. Lydia H. Pecker is a pediatric hematologist and Director of the Young Adult Clinic at the Sickle Cell Center for Adults at Johns Hopkins. Dr. Pecker received her undergraduate degree in Africana studies from Brown University and earned her M.D. at the University of Pennsylvania School of Medicine. She completed residency training at Children’s Hospital at Montefiore and completed a fellowship at Children’s National Medical Center and the National Institutes of Health’s National Heart, Lung and Blood Institute before joining the Hopkins faculty in 2016. Dr. Pecker's NIH and foundation-funded research focuses on reproductive health in people with ovaries and sickle cell disease. Dr. Pecker is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Tubal Ligation, and Bone Marrow Transplant. Dr. Pecker is board certified in American Board Of Pediatrics. Dr. Pecker is currently accepting new patients.

"Dr. James Casella is a professor of pediatrics and oncology at the Johns Hopkins University School of Medicine. As the Johns Hopkins’ Rainey Professor of Pediatric Hematology, Dr. Casella is chief of the Division of Pediatric Hematology at Johns Hopkins Children's and director of the Basic and Translational Research Program in Sickle Cell Disease, Comprehensive Sickle Cell Center and the Maryland Hemophilia Treatment Center at Johns Hopkins. He supervises several labs investigating the cellular and molecular basis of pediatric blood-borne diseases. He is seeking to develop better treatments for sickle cell disease and the prevention of central nervous system complications of this disorder, including stroke. Dr. Casella received his undergraduate degree in mathematics from Union College. He earned his M.D. from SUNY of Syracuse and completed a residency in pediatrics at Johns Hopkins University School of Medicine, where he was subsequently a fellow in hematology/oncology. He has been a member of the Johns Hopkins’ faculty since 1983. A research scientist as well as a clinician, he co-directs the hematology/oncology fellowship program at Johns Hopkins Hospital and is an adjunct senior investigator (Pediatric Oncology Branch) in the Division of Clinical Sciences, National Cancer Institute, National Institutes of Health. He is also director of the NHLBI-funded K12 in benign hematology program at Johns Hopkins that trains young clinician/investigators in benign hematology and transfusion medicine. Dr. Casella has served on numerous university, hospital, and advisory committees, many geared toward hematology, pediatrics and transfusion. He has received many awards from the Johns Hopkins Hospital, including the Alexander ""Buck"" Schaffer Award for Outstanding Contribution to the Teaching of House Officers. He and a colleague created the Johns Hopkins/St. Agnes Comprehensive Hemophilia Clinic to improve care for patients with the disease.". Dr. Casella is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Casella is board certified in American Board Of Pediatrics. Dr. Casella is currently accepting new patients.

Dr. Moonjung Jung is an Assistant Professor of Medicine at the Johns Hopkins University School of Medicine. Dr. Jung graduated Summa Cum Laude from Ewha Womans University College of Medicine in Seoul, South Korea. She then completed the Internal Medicine residency training at Houston Methodist Hospital, Weill Cornell Medical College, Houston, TX and the Hematology and Medical Oncology fellowship training at National Institutes of Health, Bethesda, MD. In 2016, Dr. Jung joined the Rockefeller University as an Instructor in Clinical investigation. She received M.S. in Clinical Investigation from the Rockefeller University. In 2021, Dr. Jung joined the Johns Hopkins University School of Medicine as faculty in the Division of Hematology. Dr. Jung is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Fanconi Anemia, Congenital Aplastic Anemia, Aplastic Anemia, and Anemia. Dr. Jung is board certified in American Board Of Internal Medicine. Dr. Jung is currently accepting new patients.

Michael Streiff is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Streiff is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Venous Thromboembolism (VTE), Deep Vein Thrombosis, Pulmonary Embolism, Pancreaticoduodenectomy, and Bone Marrow Aspiration. Dr. Streiff is currently accepting new patients.

Panayotis Ledakis is a Hematologist Oncology provider practicing medicine in Baltimore, Maryland. Dr. Ledakis is highly rated in 71 conditions, according to our data. His clinical expertise encompasses Desmoplastic Small Round Cell Tumor, Anemia, Lynch Syndrome, Thrombocytopenia, and Ureteroscopy. Dr. Ledakis is board certified in American Board Of Internal Medicine - Hematology, 2000 and American Board Of Internal Medicine - Medical Oncology, 1998. Dr. Ledakis is currently accepting new patients.

Patrick Forde is a Hematologist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Forde is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, and Small Cell Lung Cancer (SCLC). Dr. Forde is currently accepting new patients.

Alison Moliterno is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Moliterno is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, and Bone Marrow Aspiration. Dr. Moliterno is currently accepting new patients.

Courtney Fitzhugh is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Fitzhugh is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant.

Christopher Hourigan is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Hourigan is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Childhood Acute Myeloid Leukemia, Bone Marrow Transplant, and Bone Graft.

Christopher Kanakry is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Kanakry is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Primary Immunodeficiency (PID), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Graft.

Jerry Spivak is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Spivak is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, and Myeloproliferative Neoplasms (MPN).

Michael Auerbach is a Hematologist practicing medicine in Rosedale, Maryland. Dr. Auerbach is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Anemia, Polycythemia Vera, Sideroblastic Anemia, and Myelodysplastic Syndrome (MDS). Dr. Auerbach is currently accepting new patients.

Maria Baer is a Hematologist Oncology specialist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Baer is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Splenectomy. Dr. Baer is board certified in American Board Of Internal Medicine - Hematology, 1984 and American Board Of Internal Medicine - Internal Medicine, 1983. Dr. Baer is currently accepting new patients.

Dr. Alexander J. Ambinder is an instructor of medicine at the Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins. Dr. Ambinder has expertise in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and bone marrow transplantation. Dr. Ambinder received his B.A. from Washington University in St. Louis. He earned his M.D. from Emory University School of Medicine and his M.P.H. from Emory University Rollins School of Public Health. He completed the Osler Medical Residency Training Program in internal medicine at Johns Hopkins and subsequently served as an Assistant Chief of Service (Chief Resident). He completed his fellowships in Hematology and Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and also served as a Chief Fellow. Dr. Ambinder is a member of the American Society of Hematology and the American Society of Clinical Oncology. Dr. Ambinder’s principle research interest is in designing and conducting clinical trials inspired by laboratory insights to improve the management of acute myeloid leukemia and myelodysplastic syndrome. He also has an interest in building large databases that will yield insights that allow for more personalized approaches to the care and treatment of patients with blood cancers. Dr. Ambinder is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Childhood Acute Myeloid Leukemia, and Bone Marrow Aspiration. Dr. Ambinder is board certified in American Board Of Internal Medicine. Dr. Ambinder is currently accepting new patients.

Dr. Katherine Rappazzo is a clinical associate in the division of hematology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include hematologic disorders such as anemia, iron deficiency, hereditary hemorrhagic telangiectasia, myeloproliferative disorders, venous thromboembolism, bleeding disorders, hypercoagulable states, thrombocytopenia, leukopenia, and disorders of iron metabolism. Dr. Rappazzo is highly rated in 1 condition, according to our data. Her clinical expertise encompasses HER-2 Positive Breast Cancer, Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Hodgkin Lymphoma, and Tissue Biopsy. Dr. Rappazzo is board certified in American Board Of Internal Medicine. Dr. Rappazzo is currently accepting new patients.

Dr. Matthew Merguerian is a pediatric hematologist specializing in bleeding and clotting disorders. His research is focused on bleeding disorders resulting from platelet dysfunction. His lab is interested in understanding the mechanisms behind platelet dysfunction and in developing platelet-targeted therapies that could alleviate abnormal bleeding or clotting. Dr. Merguerian is highly rated in 1 condition, according to our data. His clinical expertise encompasses RUNX1 Familial Platelet Disorder, Blood Clots, Acute Myeloid Leukemia (AML), and Thrombocytopenia. Dr. Merguerian is board certified in American Board Of Pediatrics. Dr. Merguerian is currently accepting new patients.

Jennie Law is a Hematologist Oncology specialist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Law is highly rated in 30 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Hemoglobin SC Disease, Hemoglobin E Disease, and Bone Marrow Aspiration. Dr. Law is board certified in American Board Of Internal Medicine - Hematology, 2015, American Board Of Internal Medicine - Internal Medicine, 2011, and American Board Of Internal Medicine - Medical Oncology, 2015. Dr. Law is currently accepting new patients.